Clinical Pharmacology & Therapeutics (journal)

December 11, 2024

Study uses AI to cast light on harmful drug-drug interactions

Using AI, a team identified a gap in post-market drug safety: not all published reports of dangerous drug interactions are taken up by recognized purveyors of drug safety information.

By Paul Govern
Members of the Kang lab include (front row from left) Melissa Deleeuw, Jing-Qiong (Katty) Kang, MD, PhD, Wangzhen Shen, MD, and Karishma Randhave, and (back row from left) Ekta Anand, Debbie Song, and Kirill Zavalin, PhD. (photo by Susan Urmy)
December 10, 2024

Therapy for genetic epilepsy in children showing promise

Preliminary results of a clinical trial of 4-phenylbutyrate (PBA) “show a significant reduction in seizure activity among participants.”

By Bill Snyder
September 2, 2021

Study shows gene-drug interactions are common

When a drug or combination of drugs causes different responses in different people, genetic variation is often at play. Pharmacogenomics, through discovery of genetic risk and use of clinical genotyping, aims to reduce trial-and-error approaches to drug prescribing.

By Paul Govern
August 12, 2021

Certain drug exposures correlate with reduced COVID severity: study

Analyzing electronic health records (EHR) of 9,748 patients diagnosed with COVID-19, Cosmin Bejan, PhD, Elizabeth Phillips, MD, and colleagues at Vanderbilt University Medical Center asked whether COVID disease severity correlated with any drugs that happened to be taken by these patients in the months leading up to their diagnosis.

By Paul Govern
From left, Dan Roden, MD, Ayesha Muhammad, Jonathan Mosley, MD, PhD, and Sara Van Driest, MD, PhD, found that a genome-wide approach can improve the prediction of drug responses.
July 22, 2021

For more precise drug treatments, ‘squeeze’ the genome: study finds

Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.

By Bill Snyder
March 28, 2019

Drug interaction causes hypotension

A muscle relaxing-drug and inhibitors of the metabolic enzyme CYP1A2 interact to cause severely low blood pressure and should not be co-prescribed, Vanderbilt investigators caution.

By Leigh MacMillan
March 31, 2016

Study looks at doctors’ response to genetic testing

A new clinical implementation study from Vanderbilt University Medical Center measures how physicians have responded to the introduction of routine genetic testing to predict patient response to the commonly prescribed antiplatelet drug clopidogrel.
By Paul Govern
March 31, 2014

E-records shed light on drug response

Electronic medical records linked to DNA biobanks are a valid resource for defining and understanding the genetic factors that contribute to drug response.
By Leigh MacMillan